Trial Profile
Phase 2b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of IV VIS410 in Addition to Oseltamivir Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Dec 2022
Price :
$35
*
At a glance
- Drugs VIS 410 (Primary) ; Aspirin; Diphenhydramine; Diphenhydramine; Diphenhydramine; Ibuprofen; Oseltamivir
- Indications Influenza A virus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Visterra
- 06 Nov 2019 Status changed from recruiting to completed.
- 15 Nov 2018 According to a Visterra media release, topline Data expected in 2019.
- 24 Aug 2018 Planned number of patients changed from 390 to 120.